Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.

BAIC has notched up an exit after the aluminium alloy component provider went public in a $47.8m offering on the Shenzhen Stock Exchange.

Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.

The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

The GV and Wuxi AppTec-backed drug development software producer floated above its range and saw its shares rise 68% on their first day of trading.